Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Silo Pharma, Inc. Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference July 26, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules July 22, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules July 19, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 July 18, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic July 16, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders July 08, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety June 26, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia June 07, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 06, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules June 05, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety June 04, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention May 21, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine May 14, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Positive Results for Intranasal PTSD Treatment April 23, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic April 10, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic March 20, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain March 18, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD February 28, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery February 14, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology February 01, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Positive Results in Alzheimer’s Disease Study January 24, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD January 04, 2024 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia December 28, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD November 21, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD November 08, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis October 16, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD October 11, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA September 20, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD September 12, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Silo Pharma Engages Clarivate for Intellectual Property and Patent Management August 10, 2023 From Silo Pharma, Inc. Via GlobeNewswire Tickers SILO Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.